News Summary

• transaction marks one of the first clinical-stage oncology acquisitions sourced, evaluated, and executed through an AI-powered drug development platform.
• In a Phase 1 study of 28 patients, DO-2 demonstrated 100% tumor shrinkage in all evaluable MET exon 14 skipping NSCLC patients (10/10).
• It also demonstrated a superior safety profile with zero Grade 4 adverse events, and a peripheral edema rate of just 5% (versus 62-82% for competitors)